Article Sidebar

PDF
Date Published: 25/02/2022
Abstract Views: 562
Views PDF: 412
DOI: https://doi.org/10.51298/vmj.v510i1.1927
Issue
Vol. 510 No. 1 (2022)
Section
Các bài báo
How to Cite
Tiến Quang, N. ., Huyền Nga, Đỗ ., & Thanh Tùng, N. . (2022). ASSESSMENT THE EFFECTIVENESS OF THE BORTEZOMIB-CONTAINING REGIMENS IN THE FIRST LINE TREATMENT OF MULTIPLE MYELOMA AT K HOSPITAL. Vietnam Medical Journal, 510(1). https://doi.org/10.51298/vmj.v510i1.1927

ASSESSMENT THE EFFECTIVENESS OF THE BORTEZOMIB-CONTAINING REGIMENS IN THE FIRST LINE TREATMENT OF MULTIPLE MYELOMA AT K HOSPITAL

Nguyễn Tiến Quang1,, Đỗ Huyền Nga1, Nguyễn Thanh Tùng1
1 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the effectiveness of bortezomib-containing regimens in the first line treatment of multiple myeloma at K hospital. Subjects and methods: A prospective descriptive study conducted on 44 multiple myeloma patients received bortezomib regimens chemotherapy at K Hospital from 05/2019 to 10/2021. Results: The average age of the patients was 59 years old, the male/female ratio: 1.1. The majority of patients admitted to the hospital because of bone pain 91%. Most of the patients had multiple lesions 88.6%. The most common injury site is the lumbar spine, 75%. The most common disease form is IgG Kappa 38.6%, IgG Lambda 18.2%. VRD and VTD regimens have high disease control rates (100% and 96.6%) while disease control rates of VCD regimens is 60%. The most common toxicity was peripheral neurotoxicity in the group treated with the VTD regimen 27.6%, the group treated with the VTD regimen often experienced leukopenia 40% and cutaneous toxicity 30%. Conclusion: Multiple myeloma treatment with bortezomib-containing regimens has a high response rate and safety.

Article Details

Keywords

multiple myeloma, bortezomib-containing regimens

References

1. Jacob P Laubach. Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis. Uptodate. 2021:1-21.
2. S Vincent Rajkumar. Multiple myeloma: Overview of management. Uptodate. 2020:1-23.
3. Durie BG HA, Abidi MH, et al.,. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519.
4. Ann E Engebretson. Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM). Blood. 2013;122(21):3178-3184.
5. Philippe Moreau, Cyrille Hulin, Margaret Macro et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016:2569–2574.
6. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003:21.
7. Shaji Kumar. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–4382.
8. Katarina Uttervall, Johanna Borg Bruchfeld, Charlotte Gran et al. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. Eur J Haematol. 2019:247-254.